Celox-A™, the new applicator for penetrating trauma wounds has now obtained a class 3 CE Mark approval allowing use in Europe.
MedTrade, Crewe, UK is proud to announce the European launch at Medica, Dusseldorf (19th -22nd Nov 08) of Celox-A.
Penetrating wounds like shrapnel or knife wounds are very difficult to treat. They can often be lethal. It is extremely difficult to get any blood clotting agent to the real source of bleeding.
Celox™-A’s patented application system now offers a solution, which allows rapid and effective treatment of life threatening bleeding. The applicator is easy and instinctive to use. It allows you to get the Celox™ granules through a small entry wound, directly to the bleeding site in just a few seconds. In clinical testing it has repeatedly shown itself to be able to quickly and reliably stop deep arterial bleeds.
Celox’s™ unique, patented and natural formula, works independently of the body’s normal clotting mechanisms to robustly clot blood even where normal blood clotting is slow or impaired.
Craig Hardy, CEO of MedTrade, said “Celox™-A was developed with advice from a member of the US Navy Seals. It has received been extremely well received in the US following its launch in April 08. I have already have reports of 2 lives being saved in Afghanistan using Celox™-A. It is now fantastic to be able to offer this solution within the EC to European police, ambulance and military medics.”
More details on Celox™ can be found on www.celoxmedical.com or contact MedTrade at Web@MedTradeProducts.co.uk
About MedTrade:- MedTrade was formed in 1999 and based in Crewe, UK, MedTrade develops, manufactures and supplies novel wound care products for professional and consumer healthcare markets around the world. www.medtrade.co.uk
This press release comes from MedTrade Products Ltd, Crewe, Cheshire, UK.
Telephone +44 1270 500019, Fax +44 1270 500045.
A range of eye catching pictures and logos are available.
Press Contact: Craig Hardy +44 7979 851401